Crohn's & Colitis Foundation

Public Interest Registry Names Five New Members to its Advisory Council

Retrieved on: 
Monday, November 21, 2022
Internet, Veteran, Trust, Public Interest Registry, Poverty, PIR, Crohn's & Colitis Foundation, Country code top-level domain, Policy, Council, Top-level domain, Registrar, ALAC, Arthritis Foundation, MarkMonitor, Advisory, Public relations, United States Olympic & Paralympic Committee, Woman, 501(c)(3) organization, Religion, Arthritis, Advisory Council, Life, SAS Institute, Telecommunication, Human, Visual impairment, Hunger, Organization, Human rights, Education, Culture, Politics, Kayla, Internet Society, Advisory Council on Historic Preservation, Pharmaceutical industry, Management, Property management, Optometry, ICANN

"We are honored to welcome our newest members to the Public Interest Registry Advisory Council from organizations around the world," said Jon Nevett, President and CEO of Public Interest Registry.

Key Points: 
  • "We are honored to welcome our newest members to the Public Interest Registry Advisory Council from organizations around the world," said Jon Nevett, President and CEO of Public Interest Registry.
  • The members are approved by the PIR Board of Directors in accordance with the Advisory Council Charter.
  • Public Interest Registry is proud to welcome the following new members to its Advisory Council:
    Andrea Abramowitz is from the United States and currently lives in Frisco, Texas.
  • In addition to these new members, the following current members will continue their service and round out the Advisory Council at nine members.

THE CANADIAN INFLAMMATORY BOWEL DISEASE RESEARCH CONSORTIUM AWARDS FIRST $1M PIONEER GRANT FROM TAKEDA CANADA

Retrieved on: 
Tuesday, November 8, 2022
Ulcerative colitis, IBD, UC, Crohn's disease, University, Volunteering, Takeda Pharmaceutical Company, Solution, CRO, Quality of life, Awareness, Risk, NYSE, Precision medicine, Impact, Hematology, Disease, Inflammation, Partnership, C1-inhibitor, Vaccine, Cumming School of Medicine, TAK, University of Calgary, TSE, Mathematical optimization, General manager, Crohn's and Colitis Canada, Clinical trial, CIRC, Pragmatism, R, Inflammatory bowel disease, Technology, Crohn's & Colitis Foundation, Genetics, Hospital, Patient, Ileum, Drug development, CD, Investment, Research, Pharmaceutical industry, Medical device, Facebook, Takeda, Colitis, Neuroscience, Gastroenterology

Funding will support the first active comparator, multicentre, randomized trial to evaluate optimal first-line treatment strategy for Ileal Crohn's disease

Key Points: 
  • Funding will support the first active comparator, multicentre, randomized trial to evaluate optimal first-line treatment strategy for Ileal Crohn's disease
    TORONTO, Nov. 8, 2022 /CNW/ - The Canadian Inflammatory Bowel Disease Research Consortium (CIRC) awards the inaugural $1 million PIONEER Grant from Takeda Canada Inc. (Takeda), in support of high-quality, impactful Canadian clinical research to improve patient outcomes and quality of life for people living with inflammatory bowel disease (IBD).
  • The grant awardee will also receive assistance from Alimentiv, a world-class research organization with deep expertise in conducting clinical trials in IBD, through expertise, research execution and in-kind support.
  • Ileal CD increases the risk for bowel damage so choosing the right medical treatment is critical for preventing complications like hospitalization and surgery.
  • "At Takeda, we are committed to advancing scientific research in the area of IBD and are proud to establish the CIRC PIONEER Grant to support Canadian researchers in their pursuit of life-changing innovations," said Rute Fernandes, General Manager, Takeda Canada.

COVID-19 Virus Increases Risk for Other Infections by Disrupting Normal Mix of Gut Bacteria

Retrieved on: 
Tuesday, November 1, 2022
MPH, Hospital, Research, Infection, COVID-19, Department, Coronavirus, NYU Langone Health, National Institutes of Health, Howard Hughes Medical Institute, Man, Severe acute respiratory syndrome coronavirus 2, Schluter, Jan, Crohn's disease, Immune system, G.H. Raisoni Department of Microbiology and Biotechnology, Book of Judith, Jan Vilček, Vedanta, Cadwell, Nature Communications, Patient, New York University Grossman School of Medicine, Yale University, The Kenneth Rainin Foundation, Genetics, Risk, Physician, Bacteria, Disease, Woman, Yale School of Public Health, National, Crohn's & Colitis Foundation, Q-system (genetics), Yale school, AbbVie, Mouse, NYU, DP2, Public health, Vaccine, Antibiotics, Pharmaceutical industry, Dietary supplement, MD, Autoimmunity, Doctor of Philosophy, Medicine, Microbiology

However, researchers say, it has remained unclear until now which came first, the coronavirus infection disrupting the gut microbiome or an already weakened gut making the body more vulnerable to the virus.

Key Points: 
  • However, researchers say, it has remained unclear until now which came first, the coronavirus infection disrupting the gut microbiome or an already weakened gut making the body more vulnerable to the virus.
  • The new investigation also revealed that antibiotic-resistant species can escape into the bloodstream, putting patients at greater risk for life-threatening secondary infections.
  • These antibiotic-resistant bacteria found in the gut were also observed to have migrated into the bloodstream in 20% of patients.
  • If any bacteria group made up a majority of the bacteria living in the gut, they were considered dominant.

Verily and Crohn’s & Colitis Foundation Expand Strategic Partnership to Establish Novel Registry of Patients With Inflammatory Bowel Disease (IBD) 

Retrieved on: 
Tuesday, October 25, 2022
Research, Technology, Genetics, Health Technology, Philanthropy, Other Health, Health, Data Management, Foundation, Science, Quality of life, Health, CDC, Data science, Disease, Crohn's & Colitis Foundation, Foundation, Patient, MBA, Research, Google, Industry, Multimedia, Partnership, Technology, Doctor of Philosophy, MD, Verily, IBD, Trial of the century, Ulcerative colitis, Inflammatory bowel disease, Solution, Cohort study, Pharmaceutical industry, Alphabet

The collaboration will focus on building a longitudinal registry to accelerate research in Crohns disease and in ulcerative colitis, collectively known as inflammatory bowel disease (IBD).

Key Points: 
  • The collaboration will focus on building a longitudinal registry to accelerate research in Crohns disease and in ulcerative colitis, collectively known as inflammatory bowel disease (IBD).
  • The registry will capture data directly from patients at time periods in their disease journeys to add depth and context to information collected in a clinical setting.
  • IBD Partners, sponsored by the Crohn's & Colitis Foundation, is a web-based partnership of over 15,000 patients with IBD.
  • The Crohn's & Colitis Foundation is the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD), with the mission of curing Crohn's disease and ulcerative colitis, and of improving the quality of life of the millions of Americans living with IBD.

AMGEN'S ANNUAL TRENDS REPORT FINDS COMPETITION CREATED BY BIOSIMILARS CONTRIBUTED $21 BILLION IN U.S. HEALTHCARE SYSTEM SAVINGS

Retrieved on: 
Wednesday, October 12, 2022
Education, Therapy, Mayo Clinic, Head, Support, NASDAQ, Lists of disasters, Patent, Crohn's & Colitis Foundation, Board of directors, Public expenditure, Failure, Solution, Adoption, News, Pandemic, Barron's, Access, Confidentiality, Marketing, Clinical trial, FDA, AMGN, Movement, Government, Growth, Biology, Research, Security (finance), Annual report, Technology, Form 10-K, Biosimilar, U.S. Securities and Exchange Commission, Genetics, BeiGene, Apremilast, Physician, Disease, Clinical professor, Dow Jones Industrial Average, Patient, Biotechnology, Form 8-K, Globalization, Report, EPS, Acquisition, IBD, Safety, 5, Forward-looking statement, COVID-19, 100 Best Workplaces in Europe, Generic drug, Fine chemical, Pharmaceutical industry, Amgen

THOUSAND OAKS, Calif., Oct. 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today released the 9th edition of its Biosimilar Trends Report, which examines the current and future state of the U.S. marketplace with biosimilars. This year, in addition to examining important trends in the U.S., the Report also highlights key considerations and learnings from the global marketplace with biosimilars. To access the full Report, visit https://www.amgenbiosimilars.com/commitment/trends-report.

Key Points: 
  • This year, in addition to examining important trends in the U.S., the Report also highlights key considerations and learnings from the global marketplace with biosimilars.
  • "Our 2022 Biosimilar Trends Report found that the marketplace with biosimilars is well established, and the U.S. is poised to see continued growth in biosimilar approvals.
  • New data from the Report confirm that biosimilar uptake in the U.S. continues to increase over time, resulting in significant market share in most therapeutic areas where biosimilars have been introduced.
  • We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

Norovirus Link to Crohn's Disease May Point to New Therapies

Retrieved on: 
Wednesday, October 5, 2022
Diamond, National Institutes of Health, Biochemistry, Howard Hughes Medical Institute, The Kenneth Rainin Foundation, Disease, Virus, Infection, Crohn's disease, Pharmacology, Crohn's & Colitis Foundation, API5, Geisinger Health System, NYU, Diarrhea, New York University Grossman School of Medicine, Patient, Rockefeller University, Research, MPH, Nature, Harvard Medical School, NYU Langone Health, Cadwell, Mouse, Immune system, Vomiting, Mutation, PureTech Health, Doctor of Philosophy, Department, National, Bacteria, Injection, Pacific Biosciences, Apoptosis, Human, Vaccine, Pharmaceutical industry, Pfizer, Takeda, Genentech, MD, Norovirus, Microbiology

Norovirus, a common infection that causes vomiting and diarrhea, is one of several viruses and bacteria thought to trigger disease onset in Crohn's patients, but the field does not know why.

Key Points: 
  • Norovirus, a common infection that causes vomiting and diarrhea, is one of several viruses and bacteria thought to trigger disease onset in Crohn's patients, but the field does not know why.
  • One clue emerged when past studies found that a certain genetic change (mutation) is present in most patients with the condition.
  • This protein adds an extra layer of protection against immune damage, so even those with the mutation can have a healthy gut.
  • However, the researchers also found that norovirus infection blocks T cell secretion of API5 in mice bred to have a rodent form of Crohn's disease, killing gut-lining cells in the process.

Darren N. Seril, MD, Ph.D. is recognized by Continental Who's Who

Retrieved on: 
Thursday, September 29, 2022
American Board of Internal Medicine, Doctor of Philosophy, American Board of Commissioners for Foreign Missions, American Gastroenterological Association, Esophagus, American College, Inflammatory bowel disease, Cleveland Clinic, Robert Wood Johnson University Hospital, Rutgers University, Internal medicine, Pancreas, Colon, Crohn's disease, Cleveland, Human, ABIM, Robert Wood Johnson Medical School, Disorder, Biology, RWJBarnabas Health, American College of Gastroenterology, Liver, Thomas Jefferson University Hospital, Patient, Pharmacology, Crohn's & Colitis Foundation, Mentorship, Continental, Stomach, Medicine, MD, Gastroenterology, Medicine

A dual board-certified, fellowship-trained physician, Dr. Seril is a gastroenterologist specializing in treating and managing inflammatory bowel disease and Crohn's disease.

Key Points: 
  • A dual board-certified, fellowship-trained physician, Dr. Seril is a gastroenterologist specializing in treating and managing inflammatory bowel disease and Crohn's disease.
  • He has advanced training in this field and also teaches fellowship students who are training in this specialty.
  • In honor of his clinical expertise, Dr. Seril has received the Patients' Choice Award (2016) and the On-Time Doctor Award (2016).
  • In light of this recognition, the doctor thanks his mentors, Kiron Das, MD, and Bo Shen, MD.

Oshi Health Names Dr. Gil Melmed to Medical Advisory Board

Retrieved on: 
Tuesday, July 26, 2022
Patient, Degenerative disease, IBD, American Gastroenterological Association, Diagnosis, Cedars-Sinai Medical Center, Food, American Board of Internal Medicine, University, American Journal, Crohn's & Colitis Foundation, Internal medicine, Crohn's disease, Ulcerative colitis, Research, Inflammatory bowel disease, The American Journal of Gastroenterology, UCLA, AGA, David Geffen School of Medicine at UCLA, Economics, Albert Einstein College of Medicine, Quality of life, University of California, Irvine Medical Center, Chairperson, GI, MS, Disease management, Science, Life, American Board of Commissioners for Foreign Missions, Medicine, Medical device, Medicine, MD, Gastroenterology

NEW YORK, July 26, 2022 /PRNewswire-PRWeb/ -- Oshi Health, the virtual specialty care company transforming gastrointestinal (GI) health outcomes and economics, today announced that Gil Melmed, MD, MS, of Cedars-Sinai in Los Angeles, has joined its medical advisory board, alongside Dr. John Allen, retired Chief Clinical Officer at the University of Michigan Medical Group and past President & Chairman of the American Gastroenterological Association (AGA).

Key Points: 
  • NEW YORK, July 26, 2022 /PRNewswire-PRWeb/ -- Oshi Health, the virtual specialty care company transforming gastrointestinal (GI) health outcomes and economics, today announced that Gil Melmed, MD, MS, of Cedars-Sinai in Los Angeles, has joined its medical advisory board, alongside Dr. John Allen, retired Chief Clinical Officer at the University of Michigan Medical Group and past President & Chairman of the American Gastroenterological Association (AGA).
  • "We have reached an inflection point in the management of IBD specifically, and of GI health in general.
  • "I am thrilled to welcome Dr. Melmed to our advisory board; his experience and insights will be critical as we expand in service to both patients and providers," said Oshi Health CEO Sam Holliday.
  • Ninety-one percent of Oshi Health members achieve symptom control in 4 months or less, in turn, driving a 98% member satisfaction level.

Renowned Dermatologist - Dr. Matt Leavitt joins Gore Range Capital as an Executive Partner

Retrieved on: 
Wednesday, July 6, 2022
General Health, Public Relations, Investor Relations, Marketing, Health, Communications, Melanoma, Trustee, Patient, University, Research, DO, Plastic surgery, American Academy, FAAD, Skin, Leavitt, Program director, Cosmetic, Practitioner, Sandra Lee (dermatologist), Industry, Central Florida, American Osteopathic Association, MHR, Founder, Skin cancer, American Osteopathic Association Bureau of Osteopathic Specialists, Crohn's & Colitis Foundation, Hair, Hair loss, National Board of Medical Examiners, Kansas City University, Newsweek, Chapter, American Academy of Dermatology, Congress, American Osteopathic College of Occupational & Preventive Medicine, American Board of Commissioners for Foreign Missions, International Society, Multimedia, Medicine, Medical device, Veterinary medicine, Ageing, Colitis, Bosley, Dermatology

Matt Leavitt, DO, FAAD, Executive Chairman and Founder of Advanced Dermatology and Cosmetic Surgery, has joined Gore Range Capital as an Executive Partner.

Key Points: 
  • Matt Leavitt, DO, FAAD, Executive Chairman and Founder of Advanced Dermatology and Cosmetic Surgery, has joined Gore Range Capital as an Executive Partner.
  • Dr. Leavitt is also the Founder and Executive Medical Advisor of Medical Hair Restoration (MHR) which merged with Bosley to become the largest surgical hair restoration practice in the U.S.
    Ethan Rigel, Founding and Managing Partner of Gore Range Capital, said, The Gore Range team is thrilled to have Dr. Matt Leavitt join us as an Executive Partner.
  • Joining Gore Range Capital as an Executive Partner is a great opportunity to continue my vision of improving the current state of healthcare.
  • The Gore Range team is thrilled to have Dr. Matt Leavitt join us as an Executive Partner.

New Data Presented at DDW 2022 Shows Nearly Two-Fold Risk of Loss of Remission in Ulcerative Colitis Patients who had Histologic Inflammation on Baseline Biopsy

Retrieved on: 
Sunday, May 22, 2022
Colon, Risk, Health, UC, Real, RWE, Crohn's & Colitis Foundation, DDW, Ulcerative colitis, Patient, Colonoscopy, Index, University of Colorado School of Medicine, Crohn's disease, Associate, Adult, Inflammatory Bowel Diseases, Research, IBD, Ulcer, Recurrence, Hepatology, Systemic inflammation, Histology, Female, Real world data, Cohort analysis, Colorado School of Public Health, University, Publication, Division, Acid erosion, Steroid, Inflammation, Prevalence, Target, Diagnosis, Gastrointestinal tract, Rectum, Erosion, Mouth, LOR, Pharmaceutical industry, Medical device, Gastroenterology

Target RWE's IBD study & real world data presented at DDW 2022 included more than 500 patients with Ulcerative Colitis.

Key Points: 
  • Target RWE's IBD study & real world data presented at DDW 2022 included more than 500 patients with Ulcerative Colitis.
  • The study found that among patients in endoscopic remission, histologic inflammation was associated with a two-fold increased risk of subsequent LOR.
  • "We sought to uncover factors predictive of relapse and found histologic inflammation despite endoscopic remission to be an important risk factor for subsequent LOR.
  • Future research should focus on determining if treatment modification or intensification may be effective at preventing LOR in certain patients."